Search research articles
Contact Us
Filters
Showing results (51-60 of 70) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, et al.
The Lancet. Oncology
|
December 17, 2009
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D Wolchok, Bart Neyns, Gerald Linette, et al.
Blood Cancer Journal
|
October 24, 2020
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Paul G Richardson, Hans C Lee, Al-Ola Abdallah, et al.
The Lancet. Oncology
|
November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8<sup>+</sup> T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Weiyi Peng, Leila J Williams, Chunyu Xu, et al.
Cancer Immunology, Immunotherapy : CII
|
October 11, 2005
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients
Lorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, et al.
The New England Journal of Medicine
|
June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
Caroline Robert, Luc Thomas, Igor Bondarenko, et al.
The Lancet. Oncology
|
April 5, 2015
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Plos One
|
November 3, 2018
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
Jong W Yu, Sabyasachi Bhattacharya, Niranjan Yanamandra, et al.
Molecular Cancer Therapeutics
|
July 13, 2021
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses <i>In Vivo</i>
Rocio Montes de Oca, Alireza S Alavi, Nick Vitali, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 70) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, et al.
The Lancet. Oncology
|
December 17, 2009
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D Wolchok, Bart Neyns, Gerald Linette, et al.
Blood Cancer Journal
|
October 24, 2020
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Paul G Richardson, Hans C Lee, Al-Ola Abdallah, et al.
The Lancet. Oncology
|
November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8<sup>+</sup> T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Weiyi Peng, Leila J Williams, Chunyu Xu, et al.
Cancer Immunology, Immunotherapy : CII
|
October 11, 2005
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients
Lorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, et al.
The New England Journal of Medicine
|
June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
Caroline Robert, Luc Thomas, Igor Bondarenko, et al.
The Lancet. Oncology
|
April 5, 2015
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Plos One
|
November 3, 2018
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
Jong W Yu, Sabyasachi Bhattacharya, Niranjan Yanamandra, et al.
Molecular Cancer Therapeutics
|
July 13, 2021
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses <i>In Vivo</i>
Rocio Montes de Oca, Alireza S Alavi, Nick Vitali, et al.
Page
of 7